Status:
COMPLETED
A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
21-65 years
Phase:
PHASE3
Brief Summary
Type 2 diabetes results when the body does not produce enough insulin and/or is unable to properly use the insulin it makes (insulin resistance). This study was undertaken to assess the effects of vil...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes at least 3 months prior to screening
- Blood glucose criteria must be met
- On stable dose of metformin therapy
- BMI less than or equal to 39
Exclusion
- Type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes
- Treatment with thiazolidinediones or use of insulin within the previous 3 months
- Significant illness within 2 weeks prior to dosing
- High fasting triglycerides as defined by the protocol
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00351546
Start Date
February 1 2005
End Date
December 1 2005
Last Update
May 7 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.